


OPDIVO[®]
(nivolumab)
+ CHEMOTHERAPY



CM816 NOW APPROVED

FIRST³ AND ONLY

NEOADJUVANT IMMUNOTHERAPY
COMBINATION IN RESECTABLE NSCLC

Tumors ≥ 4 cm

OR

Node positive (N1, N2)

Regardless of PD-L1 expression^{1,2}

**3 Cycles of Neoadjuvant Opdivo
(nivolumab) + Chemotherapy¹**

OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumours ≥ 4 cm or node positive) NSCLC.

References: 1. Opdivo HSA-Approved Product Information Feb 2023 2. Forde PM, et al. N Engl J Med. 2022; 386: 1973-1985 3. Olivier T, Prasad V. Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? Transl Oncol. 2022 Oct;24:101505. doi: 10.1016/j.tranon.2022.101505. Epub 2022 Aug 4. PMID: 35953223; PMCID: PMC9381437

 Bristol Myers Squibb™

80 Marine Parade Road, #20-01/09
Parkway Parade
Singapore 449269

For Healthcare Professionals Only

1506-SG-2300012 04/23